By Holly Magna, Ph.D., Nerac Analyst,
Originally Published: November 28, 2016
New developments in Immunotherapy continue to advance and show promising results in treatment of a variety of cancers. This article reviews some of the newly marketed therapies and some still in development, as well as their complications, risks and advantages.
- 36New issue explores innovations in cancer treatments, graphene and drug safety updates. Read the full release here.
- 31By John Leavitt, Ph.D. Nerac Analyst Originally Published: August 12, 2014 In 1987, my colleagues at Stanford and I published a paper that clearly demonstrated that expression of a charge-altered mutant human beta-actin (glycine to aspartic acid substitution at amino acid 245; G245D) caused non-tumorigenic, immortalized human fibroblasts to form aggressive tumors in nude mice (Leavitt…
- 30By John Leavitt, Ph.D. Nerac Analyst Originally Published July 21, 2014 Such a protein appears to be described in a paper published in the journal Molecular Cancer Therapeutics in February 2014 by Heinz-Josef Lenz at the Keck School of Medicine of the University of Southern California in collaboration with colleagues at the University of Graz in…